<unk>  is a monoclonal antibody that is FDA approved for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.   Common adverse reactions include rash, pain in extremity, pruritus, and somnolence.
Raxibacumab
Ustekinumab
Alirocumab
Evolocumab
Lanadelumab
Durvalumab
Nebacumab
Romosozumab